Affinity Matured CRIg Variants for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRIg variants have low binding affinity for C3b, requiring high concentrations for effective complement inhibition, which limits their therapeutic efficacy in conditions involving the alternative complement pathway.
Innovation Solution
Development of CRIg variants with specific amino acid substitutions, such as Q64R and M86Y, that enhance binding affinity to C3b, resulting in improved complement inhibitory activity and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type CRIg is used, then the protein maintains natural structure and selectivity, but binding affinity to C3b is low requiring high concentrations
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the CRIg protein sequence. Mutations at positions 46, 86, and 100 (among others) alter the binding interface parameters to enhance affinity for C3b. The Q64R and M86Y substitutions specifically optimize electrostatic interactions and hydrogen bonding with C3b, reducing the concentration needed for effective complement inhibition from micromolar to nanomolar ranges.
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific positions within the CRIg binding domain rather than global modifications. The mutations are concentrated in the C2-set Ig domain where C3b binding occurs, particularly at residues that contact the C3b surface. This localized optimization maintains overall protein structure while enhancing binding affinity at the critical interface.
2Reliability
If affinity-matured CRIg variants are developed, then binding affinity and inhibitory activity increase, but protein structure complexity increases
Solution Approach 1:
The patent systematically changes amino acid parameters at specific positions to optimize binding. The affinity-matured variants use substitutions such as Q64R, M86Y, Q100R, and combinations thereof, which modify charge distribution, hydrogen bonding capacity, and van der Waals interactions at the C3b interface. These parameter changes are guided by structural data and energy calculations to achieve enhanced activity with minimal structural disruption.
Solution Approach 2:
The patent applies local quality by confining mutations to the C2-set Ig domain (residues 40-110) where C3b binding occurs, rather than modifying the entire protein. The substitutions are focused on residues that directly contact C3b or form structural scaffolds for binding, maintaining simplicity in non-binding regions while optimizing the critical interface for enhanced inhibitory activity.
3Reliability
If multiple amino acid substitutions are introduced, then binding affinity increases 30-fold, but risk of losing selectivity between C3b and C3 increases
Solution Approach 1:
The patent applies local quality by making substitutions specifically at residues that contact C3b unique structural features, such as the thioester domain and alpha-chain N-terminus, which are not present or differently configured in C3. Mutations like M86Y and Q100R target epitopes that enhance C3b binding through specific interactions (hydrogen bonds, salt bridges) that do not form with C3, thereby maintaining selectivity while increasing affinity.
Solution Approach 2:
The patent applies inversion by designing mutations that create repulsive or non-binding interactions with C3 while maintaining attractive interactions with C3b. For example, charge reversals or steric modifications at key positions are configured to favor the C3b conformation specifically, using the structural differences between C3 and C3b to the advantage of selectivity rather than generality.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.